Astellas Antifungal Isavuconazole In Line For 12-Year Exclusivity: QIDP+Orphan Combos Are Rare
This article was originally published in RPM Report
Executive Summary
Astellas Pharma’s isavuconazole should soon become the first antifungal therapy approved with the added exclusivity award for Qualified Infectious Disease Products under the GAIN Act. It will also be the first product to receive both QIDP and Orphan Drug exclusivity – a combination that probably won’t happen often.
You may also be interested in...
The Popularity of “Special Pop”: Antibiotics Incentives and PDUFA V
The Infectious Diseases Society of America’s “Special Population” approval mechanism has proponents within FDA and industry. That makes it look like a good balancing proposal to complement the market incentives for anti-infectives being pushed under the GAIN Act add-on to PDUFA V. There is one big hurdle, however: GAIN’s major legislative proponent, Rep. Phil Gingrey (R-GA) does not like the limitations on use post-approval.
House ALS Bill Would Require US FDA ‘Action Plan’ – But Not Conditional Approval
US House of Representatives if moving forward with a bill to respond to advocacy from ALS patients for more attention from FDA. The bill focuses on planning and scientific support, not new pathways.
Providers Still See Drawbacks To Opioid Education Mandates
Participants in a US FDA meeting on opioid REMS did not treat a move to mandatory education as a foregone conclusion. Instead, they delved frequently into alternate approaches to enhance the education itself.